ClinicalTrials.gg

Program

ganfeborole

In GlaxoSmithKline’s pipeline, Leucyl t-RNA synthetase inhibitor. Its studies are mostly in Tuberculosis, led by GlaxoSmithKline.

Furthest: phase 1, since Aug 21, 20261 company-led study, 1 open or runningNext primary completion: Nov 17, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline11 open or runningphase 1since Aug 21, 2026Aug 21, 2026Nov 17, 2026phase 1 · NCT07784894
  • Named in GlaxoSmithKline’s own pipeline as ganfeborole GSK3036656, phase 2, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 21, 2026First study: phase 1 study in TuberculosisFirst studyNCT07784894 · 28 planned · Spain

Ahead

  1. Nov 17, 2026Primary completion: phase 1 study in TuberculosisNCT07784894

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Leucyl t-RNA synthetase inhibitor”the company's pipeline, read by Claude · source

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07784894Tuberculosis · Spain1RecruitingNov 17, 202628

How it is read

Names in the registry

  • “Ganfeborole”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.